Navigation Links
Indian Court Refers Novartis Plea for Patent on Anti-cancer Drug to a Separate Board

The Madras High Court in the southern Indian state of Tamil Nadu has decided to transfer the Novartis AG’s appeal against the rejection of its patent// plea for the anti-cancer drug Glivec to the Intellectual Property Appellate Board.

The decision could be considered a temporary setback to the pharma multinational.

For it cannot hope for any early decision on the patent plea. The Appellate Board’s ruling too can be challenged it in the courts.

To add to Novartis’ miseries the technical member of the new appellate court will be none other than Chandrasekaran, former Controller General of the Indian Patent Office, who had rejected its application for Glivec patent. A spokesperson of the Novartis has already expressed concern over Chandrasekaran’s appointment.

The Madras High Court has already reserved its orders on the main petition by the Novartis challenging the constitutional validity of the Section 3(d) of the Patents (Amendment) Act.

Novartis contends the amendment contravenes the trade-related intellectual property rights (TRIPS) and also Article 14 of the Indian Constitution, which ensures equality before the law.

The section 3(d) of India’s 2005 Patent Amendment Act interprets the trade-related intellectual property rights (TRIPS) treaty. It prohibits patents for a new form of a known substance unless that new form has considerably better efficacy.

Novartis’s Glivec was a new form of an older molecule that it first patented in 1993. The enhancement in efficacy over the old form was not large enough to warrant a patent, the Patent Controller of India held in January last year.

The company then approached Madras High Court as the Controller’s office is situated in Chennai. It wanted rejection of patent application set aside. That appeal goes before the appellate board set up by the government of India for the purpose.

But orders on the Novartis’ challenge
'"/>




Page: 1 2 3

Related medicine news :

1. Indian Prime Minister has successful Knee Replacement Surgery
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Indian Doctor granted US patent on organ regeneration
4. Heart attack kills one in every 10 Indians
5. Indian Cherry: Richest Source of Vitiamin C
6. Indian Nationals with Foreign Medical Degrees can now practice in India
7. An Indian Bride with signs of SARS
8. Are Indians aware of SARS ?
9. Indians Stay Away from Coke, Pepsi After Toxin Scare
10. Indian pharma industry upbeat on WTO drug deal
11. Indian Treatment for Iraqi Babies
Post Your Comments:
(Date:7/22/2014)... July 22, 2014 Getting breast implants is ... completely optional or due to medical necessity. Either way, women ... to prepare for it, says Robert Kraft, MD, Plastic Surgeon ... implant removal surgeries are performed each year in the United ... 70 percent of those procedures stem from three main problems: ...
(Date:7/22/2014)... Southlake, TX (PRWEB) July 22, 2014 ... proving to address skin laxity with results that are ... opposed to topically treating the skin with radio frequency, ... probes which are inserted under the skin to “inject” ... studies have shown that this single treatment solution for ...
(Date:7/21/2014)... (PRWEB) July 22, 2014 On Monday, September ... Charity Golf Outing honoring Mike McGuriman-Motorola Solutions at The Knoll ... outing begins with registration and lunch at 11 a.m. ... and prizes. Price increases to $250 after September 7th. ... for $100 per person. The dinner will include a ...
(Date:7/21/2014)... (PRWEB) July 21, 2014 PowerObjects, ... service, support, education, and add-ons for Microsoft Dynamics ... Inner Circle, an elite group of the most ... with sales achievements that rank them in the ... of partners. Members of the Microsoft Dynamics Inner ...
(Date:7/21/2014)... human nature to hate losing. , Unfortunately, it,s ... abandoning a solid strategy and thus increasing your chances ... conclusion of a Brigham Young University study published this ... finding is based on an analysis of two decades ... focused on whether coaches adjusted their personnel following games ...
Breaking Medicine News(10 mins):Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 2Health News:Is Breast Implant Removal Right for You? Plastic Surgeon Dr. Robert Kraft With Advanced Dermatology, PC Explains Breast Implant Removal and Offers Tips On Procedure 3Health News:New Minimally Invasive Procedure, ThermiTight, “Injects” Radio Frequency to Treat Skin Laxity 2Health News:7th Annual Push to Walk Golf Outing to Be Held September 22nd 2Health News:PowerObjects Joins the 2014 Microsoft Dynamics Inner Circle 2Health News:'Moral victories' might spare you from losing again 2
... HealthDay Reporter , TUESDAY, May 17 (HealthDay News) ... birth defects in women taking these drugs during the first ... the drugs are relatively new, further studies are needed to ... In a large study of children born in Denmark, ...
... City, the prevalence of asthma among children entering school ... children growing up within walking distance of each other ... asthma. In the first comprehensive effort to understand ... Mailman School of Public Health compared the household presence ...
... . , Pediatric and young adult leukemia and ... the Cole Foundation,s announcement that it would provide more than ... four McGill University young scientists. "The Cole Foundation is dedicated ... the age of 25, and the research projects we finance ...
... from Boston University School of Medicine (BUSM) have discovered ... syndromes. The team connected pharmacological properties of the Novartis ... for the first time after investigating adverse reactions suffered ... treatment of osteoporosis. These findings appear online in the ...
... -- A gene variation that causes faulty cholesterol regulation also ... may be a reason why some women can,t get pregnant, ... more than 200 infertile women who were undergoing in vitro ... the scavenger receptor class B type 1 (SCARB1) gene. ...
... the intermittent interruption of breathing that occurs in patients with ... cells and increased tumor growth in mice, according to researchers ... mouse models tended to contain more dead cells, indicating a ... the study will be presented at the ATS 2011 International ...
Cached Medicine News:Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 2Health News:Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study 3Health News:Cockroach allergens in homes associated with prevalence of childhood asthma in some neighborhoods 2Health News:Cole Foundation injects $700,000 into childhood cancer research 2Health News:Gene Variation May Explain Some Female Infertility Cases 2Health News:Obstructive sleep apnea linked to cancer growth in mice 2Health News:Obstructive sleep apnea linked to cancer growth in mice 3
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: